Spots Global Cancer Trial Database for alk positive
Every month we try and update this database with for alk positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | NCT02227940 | Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China | NCT03909971 | Carcinoma, Non-... | Lorlatinib | 18 Years - | Pfizer | |
| Expanded Access to Ensartinib for Participants With ALK+ NSCLC | NCT04146571 | Non-Small Cell ... ALK Gene Rearra... | Ensartinib | 18 Years - | Xcovery Holdings, Inc. | |
| Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance | NCT03833934 | Non-Small Cell ... | Plasma Next Gen... | 18 Years - | Addario Lung Cancer Medical Institute | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | NCT02201992 | ALK Gene Rearra... ALK Gene Transl... ALK Positive Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Clinical Observ... Crizotinib Laboratory Biom... | 18 Years - | Eastern Cooperative Oncology Group | |
| Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) | NCT02299505 | Non-Small Cell ... | ceritinib | 18 Years - | Novartis | |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer | NCT02321501 | ALK Positive Locally Advance... Metastatic Mali... ROS1 Gene Rearr... Stage IIIB Lung... Stage IV Lung N... | Ceritinib Everolimus Laboratory Biom... Pharmacological... | 18 Years - | M.D. Anderson Cancer Center | |
| Crizotinib in ALK Rearranged Non-small-cell Lung Cancer | NCT04317651 | Non Small Cell ... Advanced Cancer Metastatic Canc... | 18 Years - | Fondazione Ricerca Traslazionale | ||
| Study of Plasma NGS for Assessment, Characterization, Evaluation of Patients With ALK Resistance | NCT03833934 | Non-Small Cell ... | Plasma Next Gen... | 18 Years - | Addario Lung Cancer Medical Institute | |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors | NCT04644315 | Neoplasms Colorectal Neop... Melanoma Pancreatic Neop... Sarcoma Ovarian Neoplas... Brain Neoplasms Thyroid Neoplas... Neuroendocrine ... Cholangiocarcin... Salivary Gland ... Head and Neck N... Thyroid Cancer,... Lymphoma, Large... Neoplasms by Si... Respiratory Tra... Thoracic Neopla... Respiratory Tra... Carcinoma, Bron... Bronchial Neopl... Intestinal Neop... Gastrointestina... Digestive Syste... Digestive Syste... Gastrointestina... Colonic Disease... Intestinal Dise... Central Nervous... | Alectinib | 18 Years - | Hoffmann-La Roche | |
| Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) | NCT02201992 | ALK Gene Rearra... ALK Gene Transl... ALK Positive Stage IB Non-Sm... Stage II Non-Sm... Stage IIA Non-S... Stage IIB Non-S... Stage IIIA Non-... | Clinical Observ... Crizotinib Laboratory Biom... | 18 Years - | Eastern Cooperative Oncology Group | |
| Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer | NCT05132218 | ALK Positive NSCLC Stage III... NSCLC Stage IV | Ensatinib | 18 Years - | Peking University Cancer Hospital & Institute | |
| Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | NCT05948462 | Lung Cancer Non-small Cell ... | Lorlatinib Cisplatin or Ca... Pemetrexed | 18 Years - | SCRI Development Innovations, LLC | |
| Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer | NCT02227940 | Advanced Malign... ALK Positive Metastatic Panc... Stage III Pancr... Stage IV Pancre... | Ceritinib Cisplatin Gemcitabine Hyd... Laboratory Biom... Paclitaxel Albu... Pharmacological... | 18 Years - | Roswell Park Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
